skgf_presentation_the role of formulations in biologics patent protection_08
DESCRIPTION
TRANSCRIPT
![Page 1: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/1.jpg)
Timothy J. Shea, Jr. � DirectorElizabeth Haanes - DirectorSterne, Kessler, Goldstein & Fox P.L.L.C.
IBC�s 8th Annual Conference on Formulation Strategies for Protein Therapeutics
Anaheim, CASeptember 24, 2008
The Role of Formulations in Biologics Patent Protection
![Page 2: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/2.jpg)
2
Introduction
� Introduction of the concept of patent life cycle management
� Insights from the pharma industry
� Key patentability issues in patent life cycle management
� The role of formulations in biologics patent protection� Case Studies
� Erythropoietin
� Growth hormone
![Page 3: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/3.jpg)
3
The Dilemma
� The cost to develop a drug or biologic and bring to market is hundreds of millions of $$$
� Patent protection for the basic NCE or protein is generally sought very early in the R&D process
� Due to the extensive regulatory review period, significant patent term has been lost by the time the product goes to market
![Page 4: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/4.jpg)
4
Patent Life-Cycle Management
� Strategic use of patents to maintain product exclusivity and revenue stream over life of blockbuster drug or biologic
� Involves obtaining additional patents that extend protection beyond the original patents covering the NCE or biologic per se
![Page 5: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/5.jpg)
5
Insights from the Pharma Industry
� Patent life-cycle management is a familiar concept for big pharma
� Hatch-Waxman Act
� Recognizes regulatory delay
� Allows innovator to extend patent term of single patent up to 5 years
� BUT, provides for generic entry immediatelyupon expiration of patent coverage
� Generics often seek to market upon expiration of original patent to NCE
![Page 6: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/6.jpg)
6
Insights from Pharma Industry
� Pharma companies have countered generics by increasing the breadth and complexity of the patent �fence� around their crown jewels� �traditional� protection covered NCE, method of
making, method of using (treating), and a pharmaceutical formulation
� Today, patents are typically also filed on:� New indications
� Polymorphs
� Mechanisms of action
� Combination products/therapies
� Dosing regimens
� Dissolution/bio profiles
� NEW FORMULATIONS 0 very important
� Methods of stabilizing
![Page 7: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/7.jpg)
7
Insights from Pharma Industry
� Novel formulations are extremely valuable to patent life cycle management
� Example: individual isomers are generally more potent than racemic mixtures
� Currently no formal legal/regulatory framework for approving generic biologics @ but it�s coming� pending legislation stalled pending election,
but demand for formal framework is great
![Page 8: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/8.jpg)
8
Patentability Issues
� Term of a U.S. patent now extends 20 years from the earliest effective filing date
� Issue date is irrelevant
� To extend patent coverage on the drug or biologic, the second (improvement) patent must have a later filing date than the original patent to the product
� Thus, the original patent is often prior art to the later filed application
![Page 9: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/9.jpg)
9
Patentability Issues
� To obtain an improvement patent, applicant must show claimed subject matter is novel, nonobvious, etc. over earlier patent to drug or biologic per se� Generally not difficult to show novelty
� But must be careful regarding inherent anticipation
� Focus is generally on obviousness
� KSR Int�l Co. v. Teleflex Inc., 550 U.S. ___(2007)� Supreme Court �clarified� obviousness
� Now easier for USPTO to establish prima facie case of obviousness and shift burden to applicant to prove otherwise
![Page 10: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/10.jpg)
10
Patentability Issues
� KSR v. Teleflex
� Improvement must be more than predictable use of prior art elements
� Not limited to references dealing with precise problem addressed
� Any need or problem known in the field and addressed by patent can provide reason for combining elements
� �Obvious to try� could be enough in some instances
![Page 11: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/11.jpg)
11
Patentability Issues
� In response to KSR case, USPTO established training guidelines for examiners
� Identified acceptable �rationales� to support prima facie case of obviousness:
A. Combining prior art elements according to known methods to yield predictable results
![Page 12: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/12.jpg)
12
Patentability Issues
� USPTO �Rationales� for Obviousness� B. Simple substitution of one known, equivalent
element for another to obtain predictable results� E.g. one known excipient for another?
� C. Use of known technique to improve similar products in the same way
� Application of technique to similar product must be within ordinary skill in art
� D. Applying a known technique to a known product ready for improvement to yield predictable results
� E.g. lyophilization?
� E. �Obvious to try� � choosing from a finite number of predictable solutions
![Page 13: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/13.jpg)
13
Patentability Issues
� Rebutting Obviousness Rejections� Submit technical evidence showing that subject
matter claimed in later (improvement) patent could not have been predicted to work
� Show that claimed subject matter (e.g. new formulation) has unexpected advantages (e.g., increased efficacy, stability, etc.)
� Clinical studies provide good opportunities for patenting improvements, since in vivo effect are difficult to predict
![Page 14: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/14.jpg)
14
The Role of Formulations in Biologics
Patent Protection
� Although no formal legal/regulatory framework for approving generic biologics exists, biologic innovators are already applying patent life cycle management strategies to extend patent protection on blockbuster biologics
� As in the pharma industry, formulation patents are essential components of a patent life cycle management strategy for biologics
![Page 15: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/15.jpg)
15
Case Study I � Erythropoietin (Amgen)
� U.S. Pat. No. 4,703,008� Effective filing date 12/13/83 (but 17-year term
from grant since pre-GATT)
� Claim 2: A purified and isolated DNA sequence consisting essentially of a DNA sequence
encoding human erythropoietin.
� U.S. Pat. No. 5,547,933� Effective filing date = 12/13/83 (17 year term)
� Claim 3. A non-naturally occurring erythropoietin glycoprotein product . . . having glycosylation
which differs from that of human urinary
erythropoietin.
![Page 16: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/16.jpg)
16
� U.S. Pat. No. 5,597,562 � Effective filing date = 6/3/91 (17-year
term)
� Claim 1: An oral dosage form
comprising the components:
(a) GCSF or erythropoietin;
(b) Surfactant(s)
(c) Fatty acid(s); and
(d) Enteric material,
wherein said components (a), (b) and (c) are mixed in liquid phase and lyophilized prior to combination with component (d).
Case Study I: Erythropoietin (Amgen)
![Page 17: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/17.jpg)
17
Case Study I: Erythropoietin (Amgen)
� U.S. Pat. No. 5,856,298� Effective filing date = 10/13/89 (17-year
term)
� Claim 1: An isolated biologically active
erythropoietin isoform having a single isoelectric point and having a specific number of sialic acids per molecule, said number selected from the group consisting of 1-14 . . . .
![Page 18: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/18.jpg)
18
Case Study I: Erythropoietin (Amgen)
� U.S. Pat. No. 7,217,689� Effective filing date = 10/13/89 (17 year
term)
� Claim 1: An analog of human
erythropoietin . . . comprising an amino acid sequence which differs from the amino acid sequence of human erythropoietin . . . by having one or more
additional glycosylation site(s) as compared to human erythropoietin.
![Page 19: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/19.jpg)
19
Case Study I: Erythropoietin (Amgen)
� U.S. Pat. No. 5,661,125� Effective filing date = 08/06/92 (almost 9
years after first patent) (17-year term)
� Claim 1: A stable pharmaceutical
composition comprising a solution of a therapeutically effective amount of erythropoietin and a preservative selected from the group consisting of benzyl alcohol, a paraben and phenol or a mixture thereof.
![Page 20: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/20.jpg)
20
Case Study I: Erythropoietin (Amgen)
� U.S. Pat. Pub. No. 2006/0264377� Effective filing date = 4/7/00 � If issues will expire 4/7/2020� Claim 1: A pharmaceutical composition
comprising:(a) A substantially homogenous preparation of mono-
PEGylated NESP, said mono-PEGylated NESP consisting of a polyethylene glycol moiety connected to a NESP moiety solely at the N-terminus thereof;
(b) Fewer than 5% non-pegylated NESP molecules; and
(c) A pharmaceutically acceptable diluent, adjuvant or carrier.
(NESP is a hyperglycosylated EPO analog having five changes in the amino acid sequence of rHuEPO which provide for two additional carbohydrate chains)
![Page 21: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/21.jpg)
21
Case Study II: Growth Hormone (Novo)
� U.S. Pat. No. 5,633,352� Effective filing date = 12/9/83 (17-year term)
� Claim 1: Biosynthetic ripe human growth
hormone from pituitary derived human growth hormone.
� U.S. Pat. No. 5,547,696� Effective filing date = 10/13/94 (17-year term)
� Claim 1: A pharmaceutical formulation comprising
a growth hormone in the amount of about 0.1 mg/ml to about 40 mg/ml and valine at a concentration up to about 100 mM.
![Page 22: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/22.jpg)
22
Case Study II: Growth Hormone (Novo)
� U.S. Pat. No. 5,552,385� Effective filing date = 6/5/95
� Claim 1: A pharmaceutical formulation comprising a growth hormone and Lys-
Gly-Asp-Ser (SEQ ID No: 1).
� U.S. Pat. No. 6,117,984� Effective filing date = 7/12/91
� Claim 1: Divalent cation crystals of human
growth hormone (hGH) or derivatives thereof.
![Page 23: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/23.jpg)
23
Case Study II: Growth Hormone (Novo)
� U.S. Pat. No. 5,849,704� Effective filing date = 12/16/92
� Claim 1: A pharmaceutical composition in the form of a lyophilized powder comprising a growth hormone or a derivative thereof and histidine or histidine derivative . . . .
� U.S. Pat. No. 6,022,858� Effective filing date = 1/28/92
� Claim 1: A pharmaceutical formulation comprising a human growth hormone pretreated with zinc salt
for at least one hour before addition of other components to the formulation and optionally containing lysine or calcium ion.
![Page 24: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/24.jpg)
24
Case Study II: Growth Hormone (Novo)
� U.S. Pat. No. 6,566,329� Effective filing date = 06/28/99� Claim 1: A method for preparing a soluble freeze-
dried solid preparation of hGH . . . .
� U.S. Pat. Pub. No. 2006/0257479� Effective filing date = 10/8/04� If issues, patent will expire in 2024
� Claim 1: A sustained release formulationcomprising a protein modified so as to provide a reduced clearance, wherein said protein does not comprise a methionine in which the side chain sulphur has been modified.
� Claim 2: The formulation according to claim 1, wherein said protein is a growth hormone compound.
![Page 25: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/25.jpg)
25
Conclusions
� Patent life-cycle management is the strategic use of patents to maintain product exclusivity and revenue stream over the life of a commercially valuable drug or biologic
� Successful companies will have fully integrated patent life-cycle and product life cycle programs
� Companies should consider strategic patenting both before and after marketing approval
� Formulation patents are particularly effective at extending exclusivity
� Effective patent life-cycle management requires careful attention to the timing of filings and the content of the application
![Page 26: SKGF_Presentation_The Role of Formulations in Biologics Patent Protection_08](https://reader033.vdocuments.mx/reader033/viewer/2022051611/549f0514ac79591f768b48d4/html5/thumbnails/26.jpg)
26
The Role of Formulations in Biologics Patent Protection
Thank You
Timothy J. Shea, Jr.
Elizabeth Haanes
Sterne, Kessler, Goldstein & Fox, P.L.L.C.
(202) 772-8679